A non-inferiority study compared risankizumab (intervention)…

A non-inferiority study compared risankizumab (intervention) to secukinumab (standard of care) for at least 90% improvement in plaque psoriasis symptoms. An NI margin of 12% was used. Risankizumab was found to achieve a 90% symptom improvement in 73.8% of patients and in secukinumab 65.6% of patients.  95%CI 0.8 to 38.8%). Which of the following is the best interpretation of these results. Compared to secukinumab:

A study compared an extended interval between zolendronic ac…

A study compared an extended interval between zolendronic acid infusions (every 12 weeks) for preventing skeletal lesions among patients with cancer to the standard of care (every 4 weeks). The NI margin was an absolute difference of 0.28% in the skeletal morbidity rate. Which of the following is the null hypothesis for this study?

Itepekimab was compared to placebo in a RCT for use in patie…

Itepekimab was compared to placebo in a RCT for use in patients with moderate-to-severe atopic dermatitis (i.e. severe skin inflammation and itching). The primary outcome was changes in the Eczema Area and Severity Index (EASI) score which has a minimally clinically important difference of a change in at least 6.6 points. At week 16 in the RCT, itepekimab had a mean decrease in the EASI score of 14.2 points compared to placebo (p=0.12).

It is estimated that angioedema occurs in approximately 0.1%…

It is estimated that angioedema occurs in approximately 0.1% of patients taking losartan. An investigator would like to identify potential risk factors for patients who experience angioedema while taking losartan. Which of the following study designs would be most appropriate?